Compare McKesson Corporation (MCK) vs M&T Bank Corporation (MTB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs M&T Bank Corporation — how do they compare? McKesson Corporation trades at $829.95 (market cap $97.35B), while M&T Bank Corporation trades at $248.99 (market cap $36.15B). The key difference: McKesson Corporation is far larger — about 2.7× M&T Bank Corporation's market cap, and M&T Bank Corporation pays the higher dividend (2.41%). Which is the better fit depends on your goals.
| MCK | MTB | |
|---|---|---|
Market Cap | $97.35B | $36.15B |
Sector | Health | Financials |
52-Week High | $995.69 | $254.04 |
52-Week Low | $659.01 | $178.63 |
Enterprise Value | $101.98B | — |
Dividend Yield | 0.39% | 2.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
M&T Bank (MTB) trades at $249.54, up 0.12% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong fundamentals with a P/E of 13.19 and net income margin of 30.85%, supported by robust loan growth and net interest income as highlighted in Q2 2026 results. Analyst consensus is a buy with a $253.68 price target, though the majority of ratings are hold.
The outlook for MTB is positive due to solid earnings performance and healthy credit quality, but risks include elevated costs and macroeconomic pressures. Investment opportunity lies in its valuation and dividend yield, while investors should monitor expense management and interest rate sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →
